公开(公告)号：EP2101823A2

公开(公告)日：2009-09-23

申请号：EP08701020.3

申请日：2008-01-08

申请人： Curevac GmbH

发明人： HOERR, Ingmar ,  PROBST, Jochen

IPC分类号： A61K48/00 ,  C12N15/13 ,  C12N15/85 ,  C07K16/28 ,  C07K16/32 ,  A61K39/395

CPC分类号： C07K16/1027 ,  A61K9/0019 ,  A61K39/395 ,  A61K39/39558 ,  A61K39/40 ,  A61K39/42 ,  A61K48/00 ,  A61K48/005 ,  A61K48/0066 ,  A61K48/0075 ,  A61K2039/505 ,  A61K2039/51 ,  A61K2039/53 ,  C07K16/1018 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/30 ,  C07K16/3046 ,  C07K16/3061 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  Y02A50/388 ,  Y02A50/41 ,  Y02A50/412

摘要： The present application describes an antibody-coding, non-modified or modified RNA and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, auto-immune diseases, virus diseases and monogenetic diseases, e.g. also in gene therapy. The present invention furthermore describes an in vitro transcription method, in vitro methods for expression of this antibody using the RNA according to the invention and an in vivo method.

公开(公告)号：EP2197481A2

公开(公告)日：2010-06-23

申请号：EP08838033.2

申请日：2008-10-08

申请人： CureVac GmbH

发明人： BARNER, Marijke ,  PROBST, Jochen ,  LANDER, Thomas ,  HOERR, Ingmar

IPC分类号： A61K39/00

CPC分类号： A61K39/0011 ,  A61K2039/53 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/70

摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.

摘要翻译： 本发明涉及到活性（免疫刺激）组合物包含至少一种RNA，优选mRNA的一个，编码至少两种（优选不同的）抗原能够在（自适应）在哺乳动物的免疫应答引发的。 本发明进一步更涉及一种疫苗，其包含所述活性（免疫刺激）组合物，以及使用所述活性（免疫刺激）组合物（用于疫苗的制备）和/或疫苗的在（自适应），用于免疫应答引发 治疗肺癌，特别是非小细胞肺癌（NSCLC），优选三个主要的子类型鳞状细胞肺癌，腺癌和大细胞肺癌，或与其相关的病症组成的组。 最后，本发明涉及试剂盒，特别是零件的试剂盒，含有活性（免疫刺激）组合物和/或疫苗。

公开(公告)号：EP2176408B9

公开(公告)日：2015-11-11

申请号：EP09705604.8

申请日：2009-01-28

申请人： Curevac GmbH

发明人： KRAMPS, Thomas ,  VOSS, Söhnke ,  PROBST, Jochen ,  HOERR, Ingmar

IPC分类号： C12N15/09 ,  C12N15/11 ,  A61K39/39

CPC分类号： A61K39/39 ,  A61K2039/53 ,  A61K2039/55561 ,  A61K2039/572 ,  C07H21/00 ,  C12N15/117 ,  C12N2310/17 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2320/31 ,  Y02A50/491

摘要： The present invention relates to nucleic acids of the general formula (I): (N u G l X m G n N v ) a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (N u G l X m G n N v ) a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.

公开(公告)号：EP2814963A1

公开(公告)日：2014-12-24

申请号：EP13704552.2

申请日：2013-02-15

申请人： Curevac GmbH

发明人： THESS, Andreas ,  SCHLAKE, Thomas ,  PROBST, Jochen

IPC分类号： C12N15/68 ,  A61K39/00 ,  A61K39/35 ,  C12N15/117

CPC分类号： A61K48/0066 ,  A61K39/00 ,  A61K48/00 ,  C07K14/505 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/24 ,  C12N15/63 ,  C12N15/67 ,  C12N15/85 ,  C12N2830/50 ,  C12N2840/105

摘要： The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein, particularly for the use in gene therapy. It also discloses its use for the preparation of a pharmaceutical composition, e.g. for use in gene therapy, particularly in the treatment of diseases which are in need of a treatment with a therapeutic peptide or protein, preferably as defined herein. The present invention further describes a method for increasing the expression of a peptide or protein comprising a therapeutic protein or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.

公开(公告)号：EP2603590B1

公开(公告)日：2014-09-10

申请号：EP11745701.0

申请日：2011-08-12

申请人： Curevac GmbH

发明人： THESS, Andreas ,  SCHLAKE, Thomas ,  PROBST, Jochen

IPC分类号： C12N15/67

CPC分类号： A61K48/0066 ,  A61K39/0011 ,  A61K2039/53 ,  A61K2039/575 ,  C07K14/435 ,  C12N15/67

摘要： The present application describes a coding nucleic acid sequence, particularly a messenger RNA (mRNA), comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g. for the use in the treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases or genetic diseases, or in gene therapy. The present invention further describes an in vitro transcription method, in vitro methods for increasing the expression of a protein using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and an ex vivo and in vivo method.

公开(公告)号：EP2603590A1

公开(公告)日：2013-06-19

申请号：EP11745701.0

申请日：2011-08-12

申请人： Curevac GmbH

发明人： THESS, Andreas ,  SCHLAKE, Thomas ,  PROBST, Jochen

IPC分类号： C12N15/67

CPC分类号： A61K48/0066 ,  A61K39/0011 ,  A61K2039/53 ,  A61K2039/575 ,  C07K14/435 ,  C12N15/67

摘要： The present application describes a coding nucleic acid sequence, particularly a messenger RNA (mRNA), comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g. for the use in the treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases or genetic diseases, or in gene therapy. The present invention further describes an in vitro transcription method, in vitro methods for increasing the expression of a protein using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and an ex vivo and in vivo method.

公开(公告)号：EP2176408B1

公开(公告)日：2015-03-11

申请号：EP09705604.8

申请日：2009-01-28

申请人： Curevac GmbH

发明人： KRAMPS, Thomas ,  VOSS, Söhnke ,  PROBST, Jochen ,  HOERR, Ingmar

IPC分类号： C12N15/09 ,  C12N15/11 ,  A61K39/39

CPC分类号： A61K39/39 ,  A61K2039/53 ,  A61K2039/55561 ,  A61K2039/572 ,  C07H21/00 ,  C12N15/117 ,  C12N2310/17 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2320/31 ,  Y02A50/491

摘要： The present invention relates to nucleic acids of the general formula (I): (N u G l X m G n N v ) a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (N u G l X m G n N v ) a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.

公开(公告)号：EP2814964A1

公开(公告)日：2014-12-24

申请号：EP13705106.6

申请日：2013-02-15

申请人： CureVac GmbH

发明人： THESS, Andreas ,  SCHLAKE, Thomas ,  PROBST, Jochen

IPC分类号： C12N15/68 ,  A61K39/00 ,  A61K39/35 ,  C12N15/117

CPC分类号： A61K39/0008 ,  A61K39/35 ,  A61K2039/53 ,  A61K2039/64 ,  C12N15/63 ,  C12N15/67 ,  C12N15/85

摘要： The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising an allergenic antigen or an autoimmune self-antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of allergies or autoimmune diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising an allergenic antigen or an autoimmune self-antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal.

公开(公告)号：EP2176408A2

公开(公告)日：2010-04-21

申请号：EP09705604.8

申请日：2009-01-28

申请人： Curevac GmbH

发明人： KRAMPS, Thomas ,  VOSS, Söhnke ,  PROBST, Jochen ,  HOERR, Ingmar

IPC分类号： C12N15/09 ,  C12N15/11 ,  A61K39/39

CPC分类号： A61K39/39 ,  A61K2039/53 ,  A61K2039/55561 ,  A61K2039/572 ,  C07H21/00 ,  C12N15/117 ,  C12N2310/17 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2320/31 ,  Y02A50/491

摘要： The present invention relates to nucleic acids of the general formula (I): (N u G l X m G n N v ) a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (N u G l X m G n N v ) a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.

公开(公告)号：EP2046954A2

公开(公告)日：2009-04-15

申请号：EP07786468.4

申请日：2007-07-31

申请人： Curevac GmbH

发明人： HOERR, Ingmar ,  PROBST, Jochen ,  KETTERER, Thomas ,  SCHEEL, Birgit

IPC分类号： C12N15/11 ,  C07H21/02

CPC分类号： A61K39/39 ,  A61K2039/55561 ,  C07H21/02 ,  C12N15/117 ,  C12N2310/17 ,  C12N2310/3515 ,  Y02A50/491

摘要： The present invention relates to a nucleic acid of the general formula (I): GlXmGn, which may be modified by a lipid. The invention relates further to a pharmaceutical composition containing an immune-stimulating agent according to the invention in combination with a pharmaceutically active carrier/vehicle (and, optionally, further auxiliary substances, additives and/or further adjuvants). The present invention can relate to a vaccine, which corresponds to a pharmaceutical composition of the invention, wherein the pharmaceutically active component induces a specific immune response (e.g. an antigen). The present invention can relate to the use of a nucleic acid of the invention or a pharmaceutical composition according to the invention for the treatment of infectious diseases, autoimmune disease, allergies or cancer diseases.